Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.
Don't forget to check out Parts 1 and 2 of our interview, where we discussed APFED, eosinophilic esophagitis (EOE), and Lori's diagnostic process. Today, in the final portion of the interview, we're…
Continue ReadingINTERVIEW: The Charge to Raise Eosinophilic Esophagitis Awareness (Pt. 3)
Did you know that July is widely considered to be Sarcoma Awareness Month? During this month, many stakeholders - from patients to researchers - aim to raise awareness of sarcomas,…
According to Cure Today, the U.S. FDA granted Orphan Drug designation to MB-106, a novel CAR-T cell therapy designed to treat Waldenström macroglobulinemia (WM). In the United States, Orphan…
In a news release, biopharmaceutical company Fulcrum Therapeutics, Inc. ("Fulcrum") shared that the first patient was dosed in the Phase 3 REACH study. Within the study, researchers are evaluating…
Continue ReadingFirst Patient Enrolled in Losmapimod Trial for FSHD
If you're just joining us, don't forget to take a look at Part 1 of this interview. In Part 1, we discussed Lori and Mary Jo Strobel, what eosinophilic esophagitis (EOE) is,…
Continue ReadingINTERVIEW: The Charge to Raise Eosinophilic Esophagitis Awareness (Pt. 2)
Food has the power to change lives, to spark connection and understanding, to raise cultural awareness, and to bring people together. Nobody knows this better than 48-year-old Lori, who spent…
Continue ReadingINTERVIEW: The Charge to Raise Eosinophilic Esophagitis Awareness (Pt. 1)
In a press release on the company website, biopharmaceutical company AbbVie shared that preliminary data was available regarding navitoclax, an investigational therapy, for individuals with primary myelofibrosis. The data…
Continue ReadingPreliminary Data Available on Navitoclax for Myelofibrosis
The ENDO 2022 Annual Congress took place from June 11-14, 2022. During the Congress, stakeholders met to discuss care, treatments, and research within endocrinology. In a news release from…
Continue ReadingICYMI: Evaluating Sogroya for Pediatric Growth Hormone Deficiency
In 2019, Courtney and Michael Henderson welcomed the newest member of their family – their son Luke. They were thrilled at this new addition, who they say is one…
From May 13-18, 2022, the American Thoracic Society (ATS) held its Annual Meeting, where researchers and stakeholders discussed research, patient care, and public health trends within the fields of…
In many cases, orally administered PDE5 inhibitors – such as Cialis, Levitra, and Stendra – have been used to treat erectile dysfunction. These vasodilating drugs were found to be…
Continue ReadingPDE5 Inhibitors Could Enhance Esophageal Cancer Treatment
The number of Alzheimer’s disease diagnoses has been rising rapidly over the last few decades. Today, an estimated 6.5 million Americans alone are living with this disease. Yet there…
Continue ReadingNew Alzheimer’s Research Could Help with Drug Development
The American Society of Clinical Oncology (ASCO) Annual Meeting (“ASCO 22”) took place this year from June 2nd through the 6th, 2022. During this Annual Meeting, stakeholders within the…
Continue ReadingEarly Findings Show DS-6000 Benefits for Ovarian Cancer, RCC
Have you ever heard of Orphan Drug designation? In the United States, this designation is granted to drugs or biologics that intend to treat, prevent, or diagnose rare diseases…
Continue ReadingVBI-1901 for Glioblastoma Granted Orphan Drug Designation
For some patients with NF2-deficient malignant pleural mesothelioma (MPM), their cancer is unresectable, meaning that it cannot be surgically removed. Finding a way to better treat and assist these…
Continue ReadingIK-930 for NF2-deficient Malignant Pleural Mesothelioma Earns Fast Track Designation
Sometimes, doctors choose to treat a certain condition with a specific medicine or class of medicines. But what happens when that medicine causes unintended and potentially harmful reactions? For…
Continue ReadingCan Immune Checkpoint Inhibitors Worsen Proteinuria in mRCC?
The last approved treatment option for Pompe disease in Europe was given approval in 2006, so 16 years ago. However, the European Commission (EC) recently approved a new therapeutic…
Pulmonary arterial hypertension (PAH) is a chronic and progressive form of high blood pressure in the lungs which can result from a number of causes: HIV, sickle cell disease,…
Continue ReadingExperimental Stem Cell Treatment Benefits Girl with PAH
Sometimes, it can be difficult to diagnose amyotrophic lateral sclerosis (ALS), a progressive neurological disease which causes nerve cell (motor neuron) death in the brain, brain stem, and spinal…
Continue ReadingCould a Muscle Biopsy Lead to Earlier ALS Diagnoses?
Unfortunately, it can sometimes be difficult to get companies to perform research and develop therapeutics for rare diseases, but the FDA came up with a process to spur research…
Continue ReadingEPX-100 for Ohtahara Syndrome Earns Orphan Drug Designation
When Ivy Reed was just two weeks old, she was first diagnosed with two conditions: non-verbal autism and propionic acidemia, the latter of which is a rare metabolic disorder. Because…
Over the last few decades, there have been immense advancements in medical technology and care options. However, not all of these advancements contribute to better patient outcomes. For example, more…
This year, the National Lipid Association held its Scientific Sessions from June 2-5, 2022. During the Scientific Sessions, attendees discussed new research, clinical best practices, and other topics within this…
Continue ReadingIs There a Link Between PAH and Metabolic Syndrome?
Did you know that atrial fibrillation (AF) increases the risk of a stroke by 3 to 5 times? However, blood thinners such as warfarin, or other potential treatments, can protect…
Continue ReadingHealth Inequities in Atrial Fibrillation Treatment
In the United States, Orphan Drug designation is granted to drugs or biologics intended to treat, diagnose, or prevent rare or life-threatening diseases or conditions. Rare conditions are those affecting…
Continue ReadingQXL138AM for Multiple Myeloma Earns Orphan Drug Designation
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Sign Up For Our Patient Panel
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.